Trial Profile
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 25 Aug 2020 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2018 Status changed from not yet recruiting to recruiting.